MBX 2982

Drug Profile

MBX 2982

Alternative Names: MBX-2982; SAR-260093

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Metabolex
  • Developer CymaBay Therapeutics
  • Class Antihyperglycaemics; Pyrimidines; Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 10 Dec 2013 Metabolex is now called CymaBay Therapeutics
  • 28 Apr 2011 MBX 2982 is no longer licensed to sanofi-aventis worldwide
  • 18 Aug 2010 Metabolex completes a phase II trial (NCT01035879) in Type-2 diabetes mellitus in USA, Georgia and India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top